Latest News and Press Releases

Revenues increased 45% compared to the previous quarter ended March 31, 2024 Optimized LungFit PH device continues to expand footprint and strengthen customer base Amir Avniel, Beyond Air Board...

GARDEN CITY, N.Y., July 31, 2024 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on...

GARDEN CITY, N.Y., July 23, 2024 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on...

GARDEN CITY, N.Y., July 16, 2024 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”) a commercial stage medical device and biopharmaceutical company focused on...

Appointed industry veteran, David Webster, as new Chief Commercial Officer Recently upgraded LungFit PH device expands customer base; revenue growth expected to accelerateeach quarter going forward ...

GARDEN CITY, N.Y., June 13, 2024 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on...

– Ongoing Phase 1a first-in-human clinical trial continues to demonstrate proof of concept for the UNO solid tumor platform with observed early tumor responses and clinical resolution of radiation...

GARDEN CITY, N.Y., May 23, 2024 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on...

HAMILTON, Bermuda, May 01, 2024 (GLOBE NEWSWIRE) -- Beyond Cancer, Ltd., a clinical stage biotechnology company developing ultra-high concentration nitric oxide (UNO) as an immunotherapeutic for...

GARDEN CITY, N.Y., March 20, 2024 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on...